drugset / Trial / NCT01368445

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

NCT01368445

Phase 3 Completed 617 enrolled Meda Pharmaceuticals
RandomizedFactorialTriple-blindTreatment

Summary

The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis.

Timeline

Start
2006-08
Primary completion
2006-11
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelastine Small molecule 822 ug Intranasal
Comparator Azelastine Small molecule 1096 ug Intranasal
Comparator Azelastine Small molecule 1644 ug Intranasal